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Objective: To determine if inspiratory capacity (IC) assessment could be useful for chronic 
obstructive pulmonary disease (COPD) patient management in the primary care setting.
Methods: A descriptive cross-sectional study was conducted in 93 patients diagnosed with 
COPD according to Spanish Thoracic Society (SEPAR) criteria. Patients were recruited in eight 
primary care centers in Andalusia, Spain. Anthropometric, sociodemographic, resting lung 
function (forced expiratory volume in one second [FEV1], forced vital capacity, synchronized 
vital capacity, IC), and quality of life data based on the Spanish version of Saint George’s 
Respiratory Questionnaire (SGRQ) were obtained.
Results: Lung function results expressed as percentages of the predicted values were as follows: 
FEV1, 49.04 (standard deviation [SD]: 16.23); IC, 61.73 (SD: 15.42). The SGRQ mean total score 
was 47.5 (SD 17.98). The Spearman’s Rho correlation between FEV1 and SGRQ was r = -0.36 
(95% confidence interval [CI]: -0.529 to -0.166), between IC and SGRQ was r = -0.329 
(95% CI -0.502 to -0.131), and between FEV1 and IC was r = 0.561.
Conclusions: Measurement of IC at rest could be used as a complementary functional exploration 
to forced spirometry in the monitorization of patients with COPD in the primary care setting. 
We found a poor correlation between IC and quality of life at the same level as in FEV1.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized 
by the loss of lung elasticity and airway narrowing resulting in airflow limitation.1,2 
This progressive airflow limitation leads to chronic air trapping and hyperinflation, 
especially during activity or exercise. Hyperinflation causes mechanical disadvantages 
since it depresses the diaphragm and impairs intercostal muscle contractility. This 
impairment increases the work and metabolic expenditure associated with breathing 
and contributes to breathlessness.3
In the diagnosis of COPD, spirometry has been used as an objective measure to 
confirm its symptom-based clinical suspicion. The diagnostic criteria for COPD include 
a forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) 
less than 70% of predicted value.1,2 FEV1 in patients with COPD is used to grade the 
severity of airway obstruction4 and as the main predictor of both disease progression 
and mortality. However, FEV1 has limited application in clinically assessing patients. 
For example, patients with mild disease (FEV1 higher than 80% of predicted value) 
or even patients with severe or very severe disease (FEV1  60% of predicted value) 
show a poor correlation between their degree of bronchial obstruction and their clinical International Journal of General Medicine 2009:2 220
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situation. In these cases patients’ quality of life (QoL) and 
survival can be conditioned by other factors.3
Regardless of the clinical usefulness of spirometry, 
clinical experience demonstrates that patients sharing very 
similar FEV1 values could show different blood gas values, 
clinical parameters, degrees of dyspnea, and very marked 
differences in QoL. These observations support the existence 
of other variables which may intervene in the pathogenesis 
or evolution of COPD. It is therefore necessary to consider 
other tests than FEV1 to asses the evolution of COPD patients. 
In these patients, other parameters such as inspiratory 
capacity (IC) may be more effective in detecting response to 
treatment, since they depend less on the degree of obstruction 
and mechanical compression associated with forced 
expiratory maneuvers.5 Previous studies have demonstrated 
the correlation between IC and the patient-centered outcomes 
of exercise tolerance and dyspnea.6
The aim of this study was to assess the usefulness of IC 
measurement in the clinical evaluation of COPD patients 
in the primary care setting. We looked for the relationship 
between the IC and FEV1 at rest and QoL in these patients.
Methods
This was a cross-sectional, observational study. Simple 
random patient sampling was carried out in COPD patients, 
following a table of random numbers, an initial list was 
selected after a search with keywords (COPD, chronic 
bronchitis, or chronic airflow obstruction) included in the 
informatic application TASS (National Health System 
application), and among those included in the integrated care 
process for COPD (COPD disease management program) 
of the Andalusian Health Council. Patients had to perform 
a pre- and postbronchodilator spirometry at the first visit in 
order to confirm their COPD diagnosis according to Spanish 
Thoracic Society (SEPAR) guidelines.2 The protocol was 
approved by ethic committee at the Puerta del Mar Hospital 
(Cádiz, Spain) and all patients provided written informed 
consent.
Patients were required to be older than 40 years and to 
have a spirometric diagnosis of COPD according to SEPAR 
guidelines. Exclusion criteria were: inability to perform the 
tests;2,7 previous history of asthma or comorbidities (neoplasm, 
other pulmonary and oropharyngeal obstructive disorders, 
tracheotomized patients, restrictive lung diseases, cardiac 
failure), and a history of exacerbation that required health 
care1,4,8 within the 30 days prior to inclusion in the study.
The study population was recruited from eight primary care 
centers in Spain: La Laguna (Cádiz); El Carmen (El Puerto de 
Santa María, Cádiz); Rodríguez Arias (San Fernando, Cádiz); 
Lucena (Córdoba); Dos Hermanas (Sevilla); Bollullos del 
Condado (Huelva); El Molino (Huelva); Fuente Blanca 
(Málaga). The inclusion period was six months.
After estimating a Pearson correlation coefficient of 
0.29 for quantitative variables (coinciding with the value 
determined in similar studies in the primary care setting 
for FEV1),9 P = 0.05, and a power of 0.80 for a bilateral 
hypothesis, the sample size was found to be 91 individuals 
(EPIDAT 3.0 software (Health Department of the Galician 
Government, Galicia, Spain). Sampling was applied to 
patients presenting criteria compatible with COPD and 
included in the TASS database and in the COPD integrated 
care program of the Andalusian health care authorities 
(Health Department of the Andalusian Government).
study variables
Information was collected regarding anthropometric (weight, 
height) and sociodemographic (age, sex) parameters, 
smoking habit, QoL, severity (as defined by SEPAR 
guidelines, patients with FEV1 expressed as percentage 
compared to reference: mild FEV1  80%; moderate 
FEV1 60%–80%; severe FEV1 40%–60%; very severe 
FEV1  40%2), specific treatment by therapeutic group 
in the preceding three months (short- and long-acting 
anticholinergics, short- and long-acting beta-adrenergics, 
inhaled/oral corticosteroids, and methylxanthines), oxygen 
therapy, adjustment of pharmacological treatment to disease 
severity according to SEPAR guidelines,2 and frequency of 
clinical exacerbations requiring attention in a primary care 
center, emergency room, or hospital admission.
Data were likewise collected on lung function as defined 
by FEV1 and IC. Testing met SEPAR recommendations.7 
Reproducibility criteria were as defined by SEPAR guidelines. 
Spirometry was derived from flow-volume loops. After a 
period of tidal breathing, subjects were instructed to inhale to 
total lung capacity and then exhale as quickly and forcefully 
as possible to residual volume and then inhale back to tidal 
volume. Exhalation was continued until lungs were emptied 
completely with absence of further flow. FEV1 was derived 
from these loops. To measure IC, subjects completed four 
tidal breaths, inhaled to total lung capacity, and then exhaled 
slowly to residual volume. Exhalation was continued until 
lungs were emptied completely with absence of further flow. 
IC was calculated through the formula: IC = synchronized 
vital capacity (SVC) – expiratory reserve volume (ERV). 
Reference values used for the different expiratory variables 
were those obtained for the Spanish population.10,11International Journal of General Medicine 2009:2 221
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Measurement instruments
Patients performed lung function testing with their usual 
pharmacological treatment. A Lilly-type Datospir 120D 
(Sibelmed, Barcelona, Spain) pneumotachometer spirometer 
was used.
To assess the COPD patients’ QoL, the Spanish version 
of St. George’s Respiratory Questionnaire (SGRQ), was 
used.12–14 This questionnaire included 50 items across 
three domains: symptoms, activity, and impact. The items 
corresponding to the symptoms domain refer to the frequency 
and severity of the respiratory symptoms. The activity domain 
addresses activity limitation due to breathlessness. The impact 
domain evaluates social functioning and psychological 
disturbances resulting from airways disease. The questionnaire 
items are presented in two ways: questions with up to five 
possible answers (only one can be chosen), or dichotomous-reply 
(yes/no) questions. The scores range from 0 to 100, with lower 
scores indicating improvement and a deviation of four units or 
more were considered to be clinically meaningful.
Data collection
After being informed about the characteristics of the study 
and the confidentiality of the data, and once written consent 
was obtained, patients were scheduled for a visit in their 
corresponding primary care centers to assess their chronic 
airflow obstruction by spirometry. They were then instructed 
not to discontinue their usual pharmacological treatment.
In the scheduled visit, sociodemographic, anthropometric, 
and smoking data were collected. Patients were asked about 
their specific pharmacological treatment (if any). Both active 
drugs and daily doses were recorded. This was followed by 
self-administration of the SGRQ and posterior lung function 
test performance. Forced spirometry comprised the record 
of three correct maneuvers according to the standards 
for lung function test performance (SEPAR guideline 
recommendations which also met American Thoracic 
Society Task Force recommendations). Patients were finally 
instructed to performance a complete exhalation until SVC 
was obtained three times.
Data was collected through a paper case report form 
(CRF) specifically designed for this study. All data were 
introduced in a Microsoft Access database (Microsoft, 
Redmond, WA, USA) and processed with the SPSS statistical 
package (v. 12.0; SPSS Inc., Chicago, IL, USA).
statistical analysis
Frequency tables for categorical variables were completed 
for our descriptive statistical study, and the mean, standard 
deviation (SD), and median for continuous variables were 
calculated. Calculation of the linear correlation coefficient 
between quantitative variables was based on the Spearman’s 
Rho statistic for nonparametric tests. Confidence intervals were 
calculated for the correlation coefficient, using the Fisher trans-
formation. The level of significance was established at 95%.
Results
The results obtained from the random selection of patients 
(Figure 1) reveal inadequate quality of the diagnostic 
registries in the primary care clinical histories with mistakes 
in diagnosis in up to 30% of the patients. Because of the 
variability in the diagnoses registered in the medical history 
it was necessary to search the patient records with keywords 
that would allow greater sensitivity in the identification of 
eligible patients. The simple random sampling before the 
inclusion guarantees the same representation of all COPD 
patients according to disease severity. In the scheduled visit, 
the investigators confirmed that patients met the diagnostic 
criteria of COPD. Patients with recent exacerbations were 
excluded in order not to affect the results.
From a random selection of individuals, 93 patients were 
included from the population with COPD registered in the 
electronic case history database (Figure 1).
Patients >40 years 
Diagnosis of COPD 
Selected patients
(n = 680)
Exclusion criteria 
(n = 178) 
Comorbidities: 76 
No COPD 
(n = 112) 
Patients scheduled
(n = 383)
No response: 43.6% 
(n = 297) 
Not located: 136
Patients studied
(n = 93)
Figure 1 study population.   Total numbers with inclusion and exclusion criteria and 
nonresponse.
Abbreviation: cOPD, chronic obstructive pulmonary disease.International Journal of General Medicine 2009:2 222
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The mean age of the 93 participants was 68.4 years 
(SD 7.8), 96.8% were male and 35.5% were current smokers. 
Their COPD severity stage had the following distribution: 
mild, 5.4%; moderate, 39.8%; severe, 39.8%; and very severe, 
15%. Pharmacological treatment followed guidelines1,2 in 
59.1% of cases.
The characteristics of the study population showed most 
patients were male with conditions amenable to improvement 
such as smoking at the time of the study and treatment 
optimization according to disease severity.
Table 1 reports the bivariant analysis of lung function 
parameters (FEV1, FEV1/FVC, IC, forced expiratory flow 
[FEF] 25%–50%) and QoL, according to severity, gender, 
and therapeutic optimization. The mean total SGRQ score 
was 47.5 (SD 17.98). Table 2 shows the correlations between 
FEV1 and IC and total SGRQ score for each degree of 
severity. The correlation coefficient between FEV1 and SGRQ 
was -0.36 (95% CI: -0.17 to -0.53), and the correlation 
coefficient between IC and SGRQ was -0.33 (95% CI: -0.13 
to -0.50). Figure 2 presents the dispersion graphics and linear 
correlation values between IC and FEV1. The statistical 
correlation between FEV1 and IC was r = 0.516.
Discussion
Misdiagnosis between COPD and other respiratory diseases 
such as asthma could cause inadequate management of these 
diseases. There are a large number of patients who enter 
primary care practices with a prior respiratory diagnosis, or 
who have received respiratory medications without a clearly 
established diagnosis.15 Data from COPD patients in previous 
epidemiological studies in Spain has shown a high COPD 
prevalence (9.1% in general population aged 40 years) 
and high rates of underdiagnosis16 (78.4%). The data 
demonstrates that most of these patients were incorrectly 
treated according to COPD guidelines.16 In this study, the 
percentage of misdiagnosis in our population was high: 
29.2% of COPD patients did not meet COPD spirometric 
diagnostic criteria. In order to efficiently identify which 
patients need further evaluation with spirometry, the general 
practitioner needs help to identify those patients who are most 
likely to have a fixed obstruction.15
Spirometry should be performed in all patients suspected 
of COPD to diagnose the disease and to assess disease 
severity. The spirometric definition of COPD includes the 
presence of a postbronchodilator FEV1/FVC  70% in order 
to confirm the presence of airflow limitation that is not fully 
reversible.17 Although these variables can be measured 
accurately and precisely in clinical research, they may be 
inconsistent in a primary care setting. This inconsistency 
may be related, at least in part, to incorrect interpretation of 
the spirometry results (only 47% of primary care physicians 
correctly interpreted spirometry results).18
As we have mentioned before, FEV1 has a poor 
correlation with clinical definition of COPD.3 In order 
to increase the correct diagnosis of patients with COPD, 
a possible alternative to FEV1 could be another parameter 
such as dyspnea, QoL, or IC. These parameters have 
established correlations with exercise tolerance and 
physical activity.
In COPD, hyperinflation or air trapping is the result of 
airway obstruction and the destruction of the lung paren-
chyma and its vasculature. In recent years, the dynamic 
hyperinflation in these patients has been recognized as a 
factor that triggers dyspnea and reduces exercise capacity. 
The degree of dynamic hyperinflation can be assessed by 
measuring reduction in IC. The measurement of IC in primary 
Table 1 Bivariate analysis of the pulmonary function results and characteristics of the patients
Variables IC FEV1 FVC FEV1/FVC FEF 25%–50%
Mean % (SD) P Mean % (SD) P Mean % (SD) P Mean % (SD) P Mean % (SD) P
Sex 0.896 0.161 0.492 0.148 0.153
  Male 62.88 (4.59) 62.00 (12.29) 69.33 (10.02) 86.67 (9.86) 40.33 (10.69)
  Female 61.69 (15.66) 48.61 (16.22) 63.47 (14.56) 71.34 (18.02) 28.49 (14.04)
Severity 0.001 0.001 0.001 0.001 0.001
  Mild 71.37 (16.09) 82.60 (2.79) 90.00 (8.09) 87.40 (12.48) 58.80 (5.02)
  Moderate 70.18 (13.71) 61.67 (6.32) 72.38 (9.11) 80.25 (15.20) 38.50 (8.77)
  severe 55.09 (11.35) 40.46 (5.69) 57.57 (9.76) 68.03 (16.19) 21.03 (6.75)
  Very severe 53.51 (16.96) 26.36 (3.41) 47.28 (9.07) 54.71 (14.95) 14.21 (5.92)
Note: Mean %, mean percentage of theoretical value.
Abbreviations: Ic, inspiratory capacity; FeV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF 25%–50%, forced expiratory flow 25%–50%; SD, standard 
deviation.International Journal of General Medicine 2009:2 223
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care settings is very rarely performed and no references were 
found in this setting to date.
Hyperinflation in early COPD is not typically discerned 
by radiography but must be assessed objectively through lung 
volume testing (ie, body plethysmography).19 Hyperinflation 
is discerned only in advanced COPD by radiography that 
shows an expanded chest, increased retrosternal air space, 
low and flat diaphragms, and decreased peripheral vascularity. 
Increased airway resistance, decreased lung elastic recoil and 
tethering properties, and premature airway closure results in 
an increased functional residual capacity (FRC).20
All COPD patients at rest show a variable degree of 
pulmonary hyperinflation, but IC reduction may have no 
consequences for gas exchange or may cause dyspnea. 
During exercise in COPD patients, the tidal volume doesn’t 
increase properly because of reduced IC and results in 
incomplete emptying of the lungs during the expiration 
(air trapping). This becomes even more important when the 
intensity of physical exercise increases (and thus ventilation) 
giving rise to dynamic hyperinflation21 and worsening of air 
trapping, dyspnea, and exercise tolerance.22 The dynamic 
hyperinflation explains the limited exercise tolerance and 
breathing difficulties observed during daily life activities in 
COPD patients.23 The administration of bronchodilators in 
some cases may not improve FEV1 but they might improve 
air trapping and consequential dyspnea and exercise 
tolerance.24,25
The results of the present study reveal the normal 
statistical distribution of IC values with dispersion of 
the values that allows correlations to be established with 
subjective measures of QoL perception. In our study, we 
observed a correlation between IC and SGRQ (-0.33; 95% 
CI: -0.13 to -0.50) showing that IC does affect the QoL 
of COPD patients. Similar correlation coefficients were 
observed between FEV1 and QoL and between IC and QoL 
as measured at rest by the SGRQ. Measurement of IC at rest 
may complement forced spirometry in the monitoring of 
patients with COPD in the primary care settings.
In contrast to parameters such as age, body mass index 
(BMI) or FEV1, a statistically significant and clinically 
relevant correlation is observed between the change in IC 
and dyspnea after exercise test (six-minute walk test).21 
These observations suggest that the measurement of IC may 
constitute an objective indicator of dynamic hyperinflation 
and air trapping in COPD.
It seems reasonable to consider the usefulness of IC, with 
equivalence to FEV1 in its correlation to QoL perception, and 
with higher correlation to FEV1 in terms of dyspnea after 
exercise testing.26 However, there is insufficient evidence on 
the reliability, reproducibility, and interindividual variability 
of IC. Moreover, and unlike that in FEV1, the cut-off points 
or percentiles allowing classification of severity of the 
obstructive lung disease, its evolution over time, and the 
severity of air trapping or hyperinflation as a function of 
IC remain to be defined. While the results of the statistical 
correlation between FEV1 and IC for the population studied 
allow us to postulate our working hypotheses, further 
studies are required taking into account prognostic variables 
relating to COPD morbidity–mortality, in order to define 
the measurement of IC as a complement to FEV1, or even 
Table 2 Determination of linear correlation coefficients of IC and FEV1 with the St. George’s Respiratory Questionnaire and disease severity
Variables FEV1 IC
Rho spearman (IC95%) P Rho spearman (IC95%) P
St. George’s Respiratory 
Questionnaire
  Total score (n = 90) -0.36 (-0.53 a -0.17) <0.001* -0.33 (-0.50 a -0.13) 0.002*
  Impact domain (n = 92) -0.28 (-0.46 a -0.08) 0.007* -0.31 (-0.48 a -0.11) 0.003*
  symptoms domain (n = 92) -0.15 (-0.34 a 0.06) 0.16 -0.15 (-0.35 a 0.05) 0.142
  Activity domain (n = 92) -0.42 (-0.57 a -0.23) <0.001* -0.32 (-0.49 a -0.12) 0.002*
Severity
  Mild (n = 5) 0.05 (-0.87 a -0.89) 0.94 0.80 (-0.28 a 0.99) 0.10
  Moderate (n = 37) -0.16 (-0.46 a 0.17) 0.34 -0.30 (-0.567 a 0.03) 0.08
  severe (n = 37) -0.38 (-0.38 a -0.06) 0.022* -0.40 (-0.642 a -0.09) 0.015*
  Very severe (n = 14) 0.07 (-0.47 a 0.58) 0.81 0.33 (-0.243 a 0.73) 0.27
Note: *statistically significant.
Abbreviations: CI, confidence interval; IC, inspiratory capacity; FEV1, forced expiratory volume in one second.International Journal of General Medicine 2009:2 224
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Figure 2 Dispersion and linear correlation values for the correlation between FeV1, 
IC, and the St. George’s Respiratory Questionnaire score.
Abbreviations: Ic, inspiratory capacity; FeV1, forced expiratory volume in one 
second.
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as an alternative to forced spirometry in those cases where 
such exploration is difficult or not possible in the primary 
care setting.
We observed a relationship between the correlations of 
FEV1 and IC with the QoL reported by COPD patients. Taking 
in mind this correlation, we believe that the measurement of 
IC in primary care may be a useful complement to forced 
spirometry in the monitoring of COPD, particularly when 
forced spirometry is difficult or impossible to perform.
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